High-density lipoprotein 3 and apolipoprotein A-I alleviate platelet storage lesion and release of platelet extracellular vesicles
Autor: | Alfred Böttcher, Armin Reidel, Annika Pienimaeki-Roemer, Evelyn Orsó, Astrid Fischer, Gerhard Liebisch, Tatiana Konovalova, Maria Tafelmeier, Gerd Schmitz |
---|---|
Rok vydání: | 2014 |
Předmět: |
medicine.medical_specialty
Catabolism Immunology Hematology Extracellular vesicle Phosphatidic acid chemistry.chemical_compound Endocrinology High-density lipoprotein chemistry Biochemistry Internal medicine Lysophosphatidic acid medicine Cholesteryl ester Immunology and Allergy lipids (amino acids peptides and proteins) Platelet Lipoprotein |
Zdroj: | Transfusion. 54:2301-2314 |
ISSN: | 0041-1132 |
DOI: | 10.1111/trf.12640 |
Popis: | Background Stored platelet (PLT) concentrates (PLCs) for transfusion develop a PLT storage lesion (PSL), decreasing PLT viability and function with profound lipidomic changes and PLT extracellular vesicle (PL-EV) release. High-density lipoprotein 3 (HDL3) improves PLT homeostasis through silencing effects on PLT activation in vivo. This prompted us to investigate HDL3 and apolipoprotein A-I (apoA-I) as PSL-antagonizing agents. Study Design and Methods Healthy donor PLCs were split into low-volume standard PLC storage bags and incubated with native (n)HDL3 or apoA-I from plasma ethanol fractionation (precipitate IV) for 5 days under standard blood banking conditions. Flow cytometry, Born aggregometry, and lipid mass spectrometry were carried out to analyze PL-EV release, PLT aggregation, agonist-induced PLT surface marker expression, and PLT and plasma lipid compositions. Results Compared to control, added nHDL3 and apoA-I significantly reduced PL-EV release by up to −62% during 5 days, correlating with the added apoA-I concentration. At the lipid level, nHDL3 and apoA-I antagonized PLT lipid loss (+12%) and decreased cholesteryl ester (CE)/free cholesterol (FC) ratios (−69%), whereas in plasma polyunsaturated/saturated CE ratios increased (+3%) and CE 16:0/20:4 ratios decreased (−5%). Administration of nHDL3 increased PLT bis(monoacylglycero)phosphate/phosphatidylglycerol (+102%) and phosphatidic acid/lysophosphatidic acid (+255%) ratios and improved thrombin receptor–activating peptide 6–induced PLT aggregation (+5%). Conclusion nHDL3 and apoA-I improve PLT membrane homeostasis and intracellular lipid processing and increase CE efflux, antagonizing PSL-related reduction in PLT viability and function and PL-EV release. We suggest uptake and catabolism of nHDL3 into the PLT open canalicular system. As supplement in PLCs, nHDL3 or apoA-I from Fraction IV of plasma ethanol fractionation have the potential to improve PLC quality to prolong storage. |
Databáze: | OpenAIRE |
Externí odkaz: |